🚨 3 new associative projects will be supported by the Mécénat Servier Charity Fund! For the second time, the Mécénat Servier Charity Fund has launched 🗣️ a call for Joint Initiatives projects at all the Group’s sites worldwide. The objective? To support long-term projects of general interest 🔥🚀, jointly developed with our local teams and financed by the Mécénat Servier Charity Fund. The Group's employees can also get involved through skills-based sponsorship missions💪 . The 3 winners are: 📍 Life Project 4 Youth with Servier Egypt & #ServierLebanon 📍 Fundación Juan XXIII with Servier España 📍 Real Pearl with Servier Magyarország #WeAreServier #charityfund #solidarity
[#ParisSaclay] "For the Servier Group, establishing R&D at Paris-Saclay means integrating a transversal, innovative, and constantly evolving innovation ecosystem." Olivier Nosjean, Head of Global Open Innovation and Scientific Affairs at Servier. Check out his interview 👇
[#PressRelease] We are pleased to announce that Servier and PRISM BioLab are entering into a drug discovery collaboration for a novel target in Oncology. Under the collaboration agreement, PepMetics™ technology provided by PRISM BioLab will be utilized to identify from their library or synthetize, characterize, and optimize small molecule compounds capable of binding and stimulating the activity of the target specified. Our commitment is to bring forward new therapeutic options for #patients, as confirmed @Véronique Blanc, PhD, Research Program Head – Immuno-Oncology at Servier: 🗣️ “Intra-cellular pathways and targets offer multiple opportunities to modulate the innate and adaptive immune response in cancer and represent a source of future innovation, that we are committed to explore.”
[#PatientView2020] We are delighted to announce that we have been ranked 35th (of 48 companies) in the Corporate Reputation of Pharma report prepared by PatientView in 2020 in collaboration with patient groups throughout the world 🌎🌏🌍. We were recognized in particular as a partner of choice in oncology; we came 8th (of 33 companies) in the ranking established by the patient groups. Our reputation with patient associations is improving particularly in the United States, where Servier Pharmaceuticals ranked 10th in the report prepared by PatientView in collaboration with patient groups in the US.
[#PressRelease] We are delighted to announce the selection of a preclinical candidate resulting from our strategic collaboration with Oncodesign to find new treatments for #Parkinson’s disease. With the selection of this first preclinical candidate, the collaboration now targets the first regulatory toxicology studies. As Ross Jeggo, Head of the Neurology & Immuno-Inflammation therapeutic area at Servier, stated: 🗣️ “Parkinson’s disease is an important part of our strategic focus, with a huge medical need and for which there are no disease progression-slowing treatments currently available. LRRK2 inhibition is a potentially disruptive mechanism that could impact and slow this progression, representing a very important hope for millions of patients worldwide”. Congratulations to the teams involved in the collaboration 👏 .
Today is #WorldEnvironmentDay! This day is organized each year by the United Nations to 🗣 raise public awareness of the urgent need to preserve our planet. This is an opportunity for us to reaffirm our commitment to reducing our environmental impact throughout our value chain and to present our projects in terms of climate contribution.
What happened in #April at Servier? 1️⃣ https://bit.ly/3elBxCC 2️⃣ https://bit.ly/2QYxZNU 3️⃣ https://bit.ly/33pxb76 4️⃣ https://bit.ly/3tjkPbm World Heart Federation Global Heart Hub
[#WorldHealthDay] Today is World Health Day and the theme for 2021 is “Building a fairer, healthier world!" Through our actions, we aim to contribute to transmit to future generations a world that can ensure access to quality health care for all. Support and share the World Health Organization campaign #HealthEquity #HealthForAll!
What happened in #February at Servier? Check out more about Servier 👉 https://servier.com/
Our ambition is to reconcile therapeutic, social, and economic performance. To make this happen, the Group has set six objectives for 2025. Siham Imani, Executive Vice President Corporate Strategy explains our challenges to achieve these objectives: ‟To achieve these objectives, we are picking up the pace of our transformation in all our activities and across our entire organization. This holistic transformation concerns not only our processes, but also the ways we work as well as our individual and collective behavior.”
